Currently, the space is dominated by Eli Lilly and Novo Nordisk, which market tirzepatide and semaglutide, respectively, and which have effectively cornered the diabetes and obesity markets for GLP-1 drugs
Tirzepatide Programs Market Pricing: Renew Bariatrics: $395 for up to 8-week vial Other programs: $450-595/month Tirzepatide typically costs more than semaglutide due to dual-action mechanism and newer technology
A1: GHK-Cu is a naturally occurring copper tripeptide found in human plasma and other body fluids, used in laboratory research to study wound healing, extracellular matrix dynamics, angiogenesis, antioxidant responses, and gene-expression changes
Catriona Reddin, the senior author and a researcher at the University of Galway in Ireland
That would be manufactured urgency, and this article doesn't do that